Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
A young man dramatically rescued by the Turkish coastguard from a sinking boat has spoken of his ordeal.
Temperatures tumbling in the clear skies
Police have launched an investigation and are trying to establish the age of the baby and how long the body has been in the drain.